LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

Oncogene, 2016 - nature.com
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20–30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …
被引用次数：67 相关文章
[PDF] vanderbilt.edu

[PDF][PDF] LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2015 - vanderbilt.edu
Lung cancer is the leading cause of cancer-related mortality worldwide and is linked to 28%
of all cancer-related deaths in the United States. 1 Despite advances in traditional …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2016 - pure.korea.ac.kr
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary… - …, 2016 - ohiostate.elsevierpure.com
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2016 - go.gale.com
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …
[HTML] nih.gov

[HTML][HTML] LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2016 - ncbi.nlm.nih.gov
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20–30% of
non-small cell lung cancer (NSCLC) patient tumors. Loss of LKB1-AMPK signaling confers …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2015 - europepmc.org
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20–30% of
non-small cell lung cancer (NSCLC) patient tumors. Loss of LKB1-AMPK signaling confers …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - …, 2016 - pubmed.ncbi.nlm.nih.gov
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2016 - go.gale.com
The tumor suppressor serine/threonine kinase 11 (STK7 7 or LKB1) is mutated in 20-30% of
patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate …

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

YM Whang, SI Park, IA Trenary, RA Egnatchik… - Oncogene, 2015 - europepmc.org
The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20–30% of
non-small cell lung cancer (NSCLC) patient tumors. Loss of LKB1-AMPK signaling confers …